Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Oncology
13m 25s
Are we ready to consider tissue agnostic treatment options in Solid Tumors
Published 11 Jul 2022
Actionable oncogenic mutations have revolutionized the treatment of many solid tumors. From the treatment driven by Biomarker derived population we are moving to tumor agnostic treatment based on shared molecular abnormality. Basket clinical trials are being carried out in patients with different tumor types but similar genetic abnormality. NTRK inhibitors targeting NTRK fusions are currently approved by FDA in tissue-agnostic way. Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers can be treated with the programmed cell death 1 (PD-1) antibody like pembrolizumab.
